Engflag

Alyr

Quick links to important sections

Alyr

Alyr_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alyr

Property Description
Active Ingredient Cetirizine hydrochloride
Forms Oral Tablet, Oral Syrup, Ophthalmic Solution
Pharmacological Class Second-generation H1-receptor Antagonist
Common Use Relief of Allergic Symptoms
Origin Synthetic, derived from hydroxyzine

What Type of Antihistamine is Alyr?

Alyr is a synthetic medicinal preparation featuring Cetirizine hydrochloride as its core active ingredient, classified as a second-generation H1-receptor antagonist within the broader antihistamine class. This pharmacological designation is fundamental to the drug's identity, signifying its ability to block the action of the key inflammatory mediator histamine. Structurally, the molecule is a piperazine derivative and a metabolite of the first-generation compound hydroxyzine, a distinction that has been clinically recognized for optimizing its effect profile.

Its essential characteristic is high selectivity for peripheral H1 receptors, which distinguishes it from older agents. This design ensures that the drug primarily acts on tissues outside of the central nervous system, providing effective, sustained H1-receptor antagonism with minimal tendency for sedation.

Composition and Available Forms

Alyr is typically a single-ingredient product featuring Cetirizine hydrochloride combined with specialized excipients. The compound is made available in multiple dosage form(s), including oral tablets, a liquid oral syrup or solution, and a dedicated ophthalmic solution.

These forms dictate the route of administration: tablets and syrup are taken orally for systemic effects across the body, while the ophthalmic solution is formulated for targeted topical use on the eyes, primarily to address local allergic conjunctivitis. The availability of liquid forms, often with mild flavoring, ensures a practical fit for patient groups, such as children, who require the same active agent but cannot manage solid oral tablets.

How Does Alyr Generally Help?

The drug’s general therapeutic purpose is to provide relief from the unwanted physical symptoms resulting from allergic reactions. It achieves this by acting as a competitive blocker that selectively occupies the H1 receptors, preventing histamine from binding and triggering the allergic response. This selective inhibition helps to neutralize the physiological cascade, and this action is utilized to reduce symptoms like excessive tearing, sneezing, and the sensation of pruritus (itching). For example, this type of medication is typically used during allergy season to control the persistent sneezing and runny nose that characterize hay fever.

Regulatory References

  1. Cetirizine: MedlinePlus Drug Information
  2. Cetirizine - StatPearls - NCBI Bookshelf

What side effects are possible with Alyr?

Possible Side Effects and Safety Information for Alyr

The safety profile for Alyr, as documented in governmental regulatory sources, classifies adverse reactions by frequency and the body's System-Organ Class (SOC) based on data from clinical trials and post-marketing surveillance.

Common and Very Common Adverse Reactions

Adverse reactions that occur frequently (Very Common: ge 1/10; Common: ge 1/100 to < 1/10) are generally categorized as those most commonly reported in clinical studies. Gastrointestinal disorders, such as nausea and vomiting, are frequently reported, particularly during the initial phase of treatment. Other common effects may include cough, headache, and upper respiratory tract infections.

Serious and Clinically Significant Safety Concerns

The most serious documented safety risk involves Drug-Induced Liver Injury and Liver Failure, with cases reported as rare but potentially fatal. Significant elevations in liver function tests have been observed. The official safety information emphasizes that Alyr should not be used in patients with severe hepatic impairment (Child-Pugh Class C) and is not recommended for those with moderate impairment.

Additionally, reports of Intracranial Hypertension have been noted in the post-marketing setting. Hypersensitivity Reactions, including anaphylaxis, have also been reported. The risk of cataracts (non-congenital lens opacities) has been identified, requiring appropriate ophthalmological monitoring.

Safety Monitoring and Restrictions

Close monitoring of liver function tests (ALT, AST, alkaline phosphatase, total bilirubin) is required before initiating and periodically during treatment. If significant elevations or signs of liver injury occur, interruption of Alyr is formally advised. Furthermore, concomitant use of Alyr with strong or moderate CYP3A inhibitors may increase exposure and risk of adverse reactions, necessitating a dosage reduction as specified in regulatory guidelines. The classification of adverse reaction frequencies strictly follows established regulatory frameworks, such as those of the EMA or FDA.

Overdose and Emergency Response

Alyr Overdose and when to seek help

Regulatory authorities document that a substantial overdose of Alyr (Cetirizine hydrochloride) typically results in pronounced central nervous system (CNS) effects, commonly occurring after ingestion exceeding five times the maximum recommended daily dose. The most frequently reported manifestations include severe somnolence, dizziness, fatigue, and malaise. Gastrointestinal disturbances such as diarrhea are also noted in official prescribing information.

Specific severe outcomes, which necessitate urgent intervention, are officially listed as potential risks, including tachycardia, convulsions, and syncope. Population-specific considerations apply: children may initially exhibit restlessness or irritability before the onset of drowsiness, and patients with underlying renal impairment face an increased risk of toxicity in overdose due to the drug’s elimination pathway.

Mandatory Emergency Action

In the event of a confirmed or suspected overdose, regulatory guidance explicitly mandates that immediate medical help must be sought, and a Poison Control Center should be contacted right away. Official documentation confirms that management is limited to symptomatic and supportive treatment. Critically, regulatory information states that no specific antidote is known to exist for Cetirizine, and the compound is not effectively removed by dialysis.

Therapeutic Uses of Alyr

What Alyr Treats: Main Uses and Benefits

Alyr is applied in situations involving certain distressing symptoms associated with various allergic conditions. It is commonly used to help with symptomatic relief for conditions presenting with systemic or localized discomfort, including allergic rhinitis (seasonal and perennial), chronic idiopathic urticaria (hives), and allergic conjunctivitis.

Therapeutic Relief and Comfort

The medication is relevant when supportive symptom management is appropriate. It is applied in addressing symptom clusters that may become intense or disruptive, including upper respiratory discomfort like repetitive sneezing, watery nasal discharge (rhinorrhea), and persistent nasal itching. It is also used in situations involving certain distressing symptoms, such as recurring pruritus and the presence of welts. It may also assist in easing ocular symptoms, such as persistent eye itching, redness, and excessive tearing.

“It is commonly used across conditions presenting with acute episodes, supporting patients during difficult episodes by easing distress.”

Alyr is relevant when supportive symptom management is appropriate, and provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Itching
Alyr is relevant for easing symptoms related to physical discomfort, such as skin and eye itching (pruritus) associated with allergic reactions.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

The eligibility for using Alyr (Cetirizine hydrochloride) is strictly defined by regulatory criteria concerning patient age, organ function, and pre-existing medical conditions.

Contraindications and Prohibitions

Alyr must not be used by individuals with a known hypersensitivity to the active substance, any excipients, or related compounds such as hydroxyzine or piperazine derivatives. Use is also formally contraindicated in patients with severe renal impairment, typically defined as a Creatinine Clearance less than 10 mL/min. Specific oral tablet formulations are also prohibited for patients with rare hereditary problems like galactose intolerance due to excipient content.

Age-Related Eligibility Rules

The medicine is generally approved for adults, adolescents 12 years of age and over, and children 6 to 11 years of age. For younger children, approved use extends down to 6 months of age for specific liquid formulations. However, solid oral tablet forms are typically not recommended for children under 6 years due to regulatory constraints regarding dose adaptation. Older adults (65 years and older) are eligible but require medical consultation due to the potential for age-related decline in kidney function.

Condition-Specific Restrictions

Use is restricted and requires conditional guidance for patients with mild to moderate renal or hepatic impairment, as eligibility shifts from standard conditions. The drug is excreted into human milk, leading to official recommendations against its use during lactation. Caution is also advised for patients with a predisposition to urinary retention or those at risk of convulsions.

What should I know about interactions with other medicines?

Alyr's interaction profile, as formally documented in regulatory information, is defined by specific pharmacodynamic ( PD) and pharmacokinetic ( PK) effects with certain substances. A documented PD interaction exists with Alcohol (Ethanol) and other Central Nervous System ( CNS) depressants. Co-administration with these agents may cause additional reductions in alertness and impairment of CNS performance due to additive effects.

In terms of PK interactions, co-administration with a high dose of Theophylline (400 mg once daily) is officially documented to result in a small (16%) decrease in Alyr's clearance. However, regulatory studies found no evidence of clinically significant pharmacokinetic interactions when Alyr was co-administered with medicines such as Azithromycin, Erythromycin, Ketoconazole, or Pseudoephedrine.

Regarding product constraints, while the extent of absorption is not modified by food, regulatory information specifies that food decreases the rate of absorption, leading to a reduction in the peak plasma concentration. Population-specific changes are also documented, as both geriatric patients and individuals with hepatic impairment formally exhibit a 40% lower clearance and a 50% prolonged elimination half-life, which establishes a distinct pharmacokinetic context for interactions in these populations.

Mechanism of Action

Highly Selective Peripheral H1 Receptor Blockade

Alyr's core mechanism is the high-affinity, competitive antagonism of the peripheral Histamine H1 receptor, effectively halting the primary signal cascade triggered by the inflammatory mediator histamine. This action immediately results in the interruption of the rapid physiological response at the tissue level.

Modulation of Vascular Dynamics and Neuronal Signaling

By blocking H1 receptors on vascular endothelial cells and sensory C-fibers, the drug modulates two critical physiological functions. This mechanism directly counteracts histamine's ability to increase vascular permeability and inhibits the stimulation of sensory C-fibers.

Confined Action and Ancillary Anti-inflammatory Effects

The mechanism features minimal penetration of the Blood-Brain Barrier (BBB), restricting its physiological influence predominantly to peripheral systems. This peripheral focus is complemented by an H1-independent effect, which directly inhibits the recruitment and migration of eosinophils, thereby contributing to the attenuation of the sustained cellular inflammatory response.

Dosage and Administration Information

Alyr is administered through several officially approved routes, reflecting the multiple dosage forms available. The administration route must align with the form: Oral (for tablets, syrups), Intravenous (IV), and Topical Ocular (for eye solution).

The standard systemic regimen for adults involves a dose of 5 mg or 10 mg taken once daily, with clinical guidelines defining 10 mg as the maximum permissible daily intake for the general population. Oral forms are administered with flexibility regarding meals, as they may be taken with or without food, although food may delay the rate at which maximum concentration is reached.

Dose adjustment is a necessary consideration for specific populations, as the drug is primarily cleared by the kidneys. General clinical practice for this agent specifies that adults with moderate-to-severe renal impairment should reduce the systemic dose to 5 mg once daily. A similar 5 mg once daily starting dose is often advised for older adults (65 and over) due to the likely age-related decline in kidney function.

For pediatric use, the total daily maximum oral dose for children aged 2 to under 6 years is 5 mg, which can be administered as a single dose or divided into 2.5 mg taken twice daily. The IV solution is designated for short-term use in acute settings and must be administered as a slow IV push over a period of one to two minutes. The topical ophthalmic solution is applied twice daily and requires the removal of soft contact lenses before application; reinsertion is permitted 10 minutes following use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Alyr (Cetirizine hydrochloride)

The clinical evaluation of Alyr, which contains cetirizine hydrochloride, is based upon numerous controlled clinical evaluations, including Randomized Controlled Trials (RCTs), comparative studies, and systematic reviews, as considered by regulatory bodies. These research efforts have explored the observation of symptoms over defined time intervals in people with specific allergic conditions.

Evidence for Use in Allergic Rhinitis (Hay Fever and Year-Round)

Research has primarily focused on the evaluation of Alyr for conditions characterized by fluctuating or episodic manifestations, such as seasonal and perennial allergic rhinitis. Studies examined the medicine compared to a placebo and to other active agents. Researchers monitored outcomes related to functional imbalance, specifically the Total Symptom Score (TSS), which is used in research exploring how symptoms change over time. The findings describe patterns observed in the studies where measurements of symptom scores were compared between the medicine group and the placebo group over short study periods (typically two to six weeks).

Evidence for Chronic Idiopathic Urticaria (Hives)

The medicine was also studied in research scenarios involving unstable symptoms, such as Chronic Idiopathic Urticaria (CIU). Studies explored outcomes reflecting daily functioning, primarily focusing on the measurement of physical discomfort from pruritus (itching) and the presence of weals (hives/welts). Some research scenarios explored short-term symptom changes in people who were classified as having symptoms persisting on the standard dose based on trial criteria, monitoring differences in scores when the dosage was temporarily adjusted.

The Evidence Base for Ocular Symptoms and Acute Relief

The specialized ophthalmic solution formulation was studied for its observation on allergic conjunctivitis. These studies measured the severity of ocular itching following controlled exposure to an allergen. Research has also explored the observation of Alyr in conditions involving periods of heightened symptoms, such as acute episodes of hives, where data show patterns related to the time taken for symptom resolution.

Research Consistency, Uncertainty, and Gaps

The body of evidence that contributes to the broader landscape for Alyr covers the short-term observation of allergic rhinitis symptoms and the immediate observation of ocular itching, with a research assessment label of High for these specific, defined endpoints. However, the evidence quality varies across studies, particularly for long-term outcomes and for data concerning doses above the licensed standard for chronic urticaria. Data for certain groups, such as children under two for seasonal allergies, remain insufficient.

Key Studies & References

  1. NICE Guideline: Chronic urticaria and angioedema

Frequently Asked Questions (FAQ)

Common questions about Alyr (FAQ)

Q: What is the main difference between Alyr and [similar drug]?

Official drug documents describe Alyr as a second-generation H1 receptor antagonist. This classification means it works mainly in the body’s peripheral system and features minimal penetration of the Blood-Brain Barrier (BBB).

Q: Does Alyr cause drowsiness or tiredness?

Drowsiness or excessive tiredness is commonly reported as a possible side effect when using this medicine. Patients are advised to note this potential effect.

Q: Can Alyr be taken on an empty stomach?

According to the official product information, the medicine can be taken with or without food. While taking it with food does not change the total amount absorbed, it may slightly delay how quickly the maximum concentration is reached in the body.

Q: Does Alyr affect my ability to drive or operate machinery?

Regulatory documents advise caution when driving a motor vehicle or operating machinery. Because drowsiness may occur, this caution is advised so that individuals may determine how the drug affects their own alertness.

Q: Can children or adolescents use Alyr?

The medication is generally approved for use in adults and adolescents 12 years and over. It is also approved for younger children, down to 6 months of age for specific formulations and conditions, but use is subject to specific official guidance.

Q: What information should I provide to a new doctor about using Alyr?

Regulatory documents indicate that information about the following areas is important for a healthcare provider to know. This includes any existing kidney or liver disease, all prescription and nonprescription medicines being used, and any plans regarding pregnancy or breast-feeding.

Q: Is Alyr used for any other purpose besides the main one?

Yes, the drug is licensed for the relief of symptoms related to both allergic rhinitis (hay fever) and chronic idiopathic urticaria (commonly known as hives or welts).

Q: What is the typical timeframe before you notice the full effect of Alyr?

Studies and official information indicate that the onset of effect is typically observed approximately 20 to 60 minutes after taking the medicine. Regulatory information indicates the effect is generally sustained over a 24-hour period.

Q: What is the difference between Alyr and a supplement for the same condition?

Alyr is a synthetic preparation formally classified by regulatory authorities as a medication, specifically an H1-receptor antagonist. Supplements, by contrast, are not regulated or classified as prescription or nonprescription medicines.

Q: Are there certain groups of people who are not eligible to take Alyr?

Yes, the official product information states that the drug must not be used by individuals with a known hypersensitivity to the drug’s components or related compounds. It is also contraindicated for those with severe renal (kidney) impairment.

Q: Do studies suggest Alyr is effective for long-term use?

Regulatory bodies have published reports noting a rare risk of severe itching upon stopping the medicine after long-term daily use (typically a few months or more). The suitability of long-term use is a factor for consideration with a healthcare professional.

Q: Why is Alyr sometimes given for [secondary approved use]?

The drug is licensed by regulatory agencies for more than one condition. For example, it is specifically approved to relieve symptoms related to chronic idiopathic urticaria, which is a key secondary licensed indication.

Q: What does the patient information leaflet say about Alyr and sun exposure?

Official warnings classify the drug's active ingredient as one of the medicines that may be associated with a phototoxic reaction. This is a skin reaction that can appear as a severe rash or exaggerated sunburn on sun-exposed areas.

Q: What is the half-life of Alyr?

The half-life refers to the time it takes for half of the drug to be eliminated from the body. In adults with normal organ function, the elimination half-life is typically stated as approximately 8 to 10 hours.

Q: Are there specific official guidelines for prescribing Alyr?

Yes. Official documents contain specific instructions for adjusting the daily dose for certain populations. This includes older adults and individuals with kidney or liver impairment, to account for differences in how their bodies process the drug.

Q: Does Alyr need to be taken at a specific time of day?

The drug is taken once a day. For consistency, the official administration information notes that it is typically taken at around the same time every day.

Q: Is Alyr excreted through the kidneys or the liver?

The medicine is primarily eliminated from the body by the kidneys (renal excretion). A portion of the drug is also processed through metabolism in the liver.

Q: Is it true that Alyr can cause [minor, non-specific side effect, e.g., dry mouth]?

Dry mouth is listed among the possible side effects that patients may experience, according to the official safety profile documents.

Q: Is Alyr a pill, a liquid, or something else?

Alyr is available in multiple dosage forms. These include oral tablets, chewable tablets, and an oral syrup (liquid), which dictates how it must be administered.

Q: Do food or certain supplements change how Alyr works?

The total amount of medicine absorbed into the body is not changed by food. There are no official interaction reports stating that food changes the drug’s overall action or effectiveness.

How should Alyr be stored and disposed of?

How to Store and Dispose of Alyr?

The storage and disposal of Alyr (Cetirizine hydrochloride) must align strictly with official regulatory requirements to ensure product integrity and public safety.

Storage Conditions

Requirement Official Instruction
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Protection Keep in the original container, tightly closed, and protect from excessive moisture and light.
Handling Liquid forms (syrup/solution) must not be frozen to prevent formulation damage.
Child Safety Store the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Alyr must be disposed of properly according to local guidelines for pharmaceutical waste, often through a drug take-back program. It is prohibited to discard the medicine via wastewater or household trash unless explicitly authorized by regulatory documents.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Alyr found in:

A-Z Index: